<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-id journal-id-type="hwp">ofids</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5782087</article-id><article-id pub-id-type="doi">10.1093/ofid/ofu051.149</article-id><article-id pub-id-type="publisher-id">ofu051</article-id><article-categories><subj-group subj-group-type="heading"><subject>IDWeek 2014 Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Oral Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>1332<break/>A Randomized, Double-Blind, Placebo-Controlled Trial of Trimethoprim-sulfamethoxazole vs. Placebo for Patients with an Incised and Drained Cutaneous Abscess</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Talan</surname><given-names>David</given-names></name><degrees>MD, FIDSA, FACEP</degrees><xref ref-type="aff" rid="sa149-af1">1</xref><xref ref-type="aff" rid="sa149-af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mower</surname><given-names>William</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="sa149-af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Abrahamian</surname><given-names>Fredrick</given-names></name><degrees>DO</degrees><xref ref-type="aff" rid="sa149-af2">2</xref><xref ref-type="aff" rid="sa149-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Krishnadasan</surname><given-names>Anusha</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="sa149-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lovecchio</surname><given-names>Frank</given-names></name><degrees>DO, MPH</degrees><xref ref-type="aff" rid="sa149-af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Karras</surname><given-names>David</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="sa149-af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Steele</surname><given-names>Mark</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="sa149-af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rothman</surname><given-names>Richard</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="sa149-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Moran</surname><given-names>Gregory</given-names></name><degrees>MD, FIDSA, FACEP</degrees><xref ref-type="aff" rid="sa149-af1">1</xref><xref ref-type="aff" rid="sa149-af2">2</xref></contrib></contrib-group><aff id="sa149-af1"><label>1</label>Emergency Medicine/Infectious Diseases, Olive View-UCLA Medical Center, Sylmar, CA</aff><aff id="sa149-af2"><label>2</label>Emergency Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA</aff><aff id="sa149-af3"><label>3</label>Emergency Medicine, Olive View-UCLA Medical Center, Sylmar, CA</aff><aff id="sa149-af4"><label>4</label>Emergency Medicine, Maricopa Medical Center, Phoenix, AZ</aff><aff id="sa149-af5"><label>5</label>Emergency Medicine, Temple University School of Medicine, Philadelphia, PA</aff><aff id="sa149-af6"><label>6</label>Emergency Medicine, Truman Medical Center/University of Kansas City, Kansas City, MO</aff><aff id="sa149-af7"><label>7</label>Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD</aff><author-notes><fn id="TN312" fn-type="con"><p><bold>Session:</bold> 184. Clinical Trials</p></fn><fn id="TN313" fn-type="con"><p>Saturday, October 11, 2014: 10:30 AM</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub" iso-8601-date="2014-12-01"><month>12</month><year>2014</year></pub-date><volume>1</volume><issue>Suppl 1</issue><issue-title>IDWeek 2014 Abstracts</issue-title><fpage seq="b">S55</fpage><lpage>S55</lpage><permissions><copyright-statement>&#x000a9; The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xlink:href="ofu051.149.pdf"/></article-meta></front><body><p><bold><italic>Background.</italic></bold>&#x02003;U.S. emergency department (ED) visits for cutaneous abscess have increased corresponding with the emergence of methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA). The role of antibiotics for patients with a drained abscess is unclear.</p><p><bold><italic>Methods.</italic></bold>&#x02003;We conducted a randomized double-blind, trial at 5 U.S. EDs to determine whether 7 days of trimethoprim-sulfamethoxazole (TMP/SMX 160 mg/800 mg BID) is superior to placebo for treatment of patients &#x0003e;12 years old with an acute uncomplicated skin abscess receiving drainage and treated as an outpatient. The primary outcome was clinical cure of the abscess at the test-of-cure visit (TOC, 7-14 days after the end of treatment) in the per-protocol (PP) population.</p><p><bold><italic>Results.</italic></bold>&#x02003;Of 1,265 patients enrolled, 1,247 (98.6%) were randomized to TMP/SMX or placebo and received &#x02265;1 dose. Subjects were median age 35 years (range, 14-73). Median maximal dimension of the abscess cavity and associated erythema were 2.5 cm and 6.5 cm, respectively; 44.3% grew MRSA. In the PP population, clinical cure occurred in 487/ 524 (92.9%) TMP/SMX-treated compared to 457/533 (85.7%) placebo-treated subjects (difference 7.2%; 95% CI 3.2%-11.2%). Similar differences were found for abscess cure in the intention-to-treat populations. Compared to the placebo group, the TMP/SMX group had lower rates of subsequent hospitalization (19/524 [3.6%] vs. 34/533 [6.4%]; difference <sup>&#x02212;</sup>2.8%; 95% CI <sup>&#x02212;</sup>5.6%-0.1%), surgeries (18/524 [3.4%] vs. 46/533 [8.6%]; difference <sup>&#x02212;</sup>5.2%; 95% CI <sup>&#x02212;</sup>8.2%-<sup>&#x02212;</sup>2.2%), new skin infections at a different location (16/524 [3.1%] vs. 55/533 [10.3%]; difference <sup>&#x02212;</sup>7.3%; 95% CI <sup>&#x02212;</sup>10.4%- <sup>&#x02212;</sup>4.1%), and similar infections in their household (9/524 [1.7%] vs. 22/533 [4.1%]; difference <sup>&#x02212;</sup>2.4%; 95% CI <sup>&#x02212;</sup>4.6%-<sup>&#x02212;</sup>0.2%) through TOC. At 42-56 days after treatment, new infection rates were 10.9% (57/524) in TMP/SMX- and 19.1% (102/533) in placebo-treated subjects (difference <sup>&#x02212;</sup>8.3%; 95% CI <sup>&#x02212;</sup>12.7%- <sup>&#x02212;</sup>3.8%). TMP/SMX was associated with slightly more, mostly mild, gastrointestinal side effects. There were no serious drug-related adverse events.</p><p><bold><italic>Conclusion.</italic></bold>&#x02003;Compared to placebo, TMP/SMX is safe and associated with improved outcomes for patients with an acute cutaneous abscess receiving drainage and treated as an outpatient.</p><p><bold><italic>Disclosures.</italic></bold>&#x02003;<bold>D. Talan</bold>, NIAID/NIH/DHHS: Research Contractor, Research support</p></body></article>